Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aptose Biosciences, Inc.

< Previous 1 2 Next >
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Third Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Results from Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Adjournment of its Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Second Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Receipt of Deficiency Notice from Nasdaq
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Results from Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the First Quarter 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Fourth Quarter and Full Year 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Reports Results for the Third Quarter 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Present at the Cantor Global Healthcare Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Tickers APTO TSX:APS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.